Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670215 · ClinicalTrials.gov registry record · Phase 3
BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 497
- Enrollment target
NCT00670215 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 497 participants.
The verdict
NCT00670215, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 497 participants
- Enrollment target
Study Summary
The primary purpose of this clinical trial is to compare in a double-blind randomized trial, the efficacy and safety of ciprofloxacin MR 1000 mg tablets given as a single-dose or as a multiple-dose regimen for the prevention of infectious complications in patients undergoing transrectal needle biopsies of the prostate (TRNBP).
Interventions
- DRUG Ciprofloxacin single dose
- DRUG Ciprofloxacin triple dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 497 participants |
| Start Date | 2004-04 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670215
The ClinicalTrials.gov registry entry for NCT00670215 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 497 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ciprofloxacin single dose is the first listed.
NCT00670215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00670215 about?
NCT00670215 is a clinical study titled "BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis". The primary purpose of this clinical trial is to compare in a double-blind randomized trial, the efficacy and safety of ciprofloxacin MR 1000 mg tablets given as a single-dose or as a multiple-dose regimen for the prevention of infectious complications in patients undergoing transrectal needle biops...
What is the current status of trial NCT00670215?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 497 participants. The study started on 2004-04. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00670215?
The interventions under investigation include: Ciprofloxacin single dose (DRUG), Ciprofloxacin triple dose (DRUG).
Who is sponsoring clinical trial NCT00670215?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.